Sign In
Buy INCY
$119.80
-0.800 (-0.663%)
At Close: Aug 05, 2026
Incyte: Valued Like A Single-Drug Company Despite Diversifying Revenue
10:24am, Tuesday, 17'th Mar 2026
Incyte is undervalued due to overemphasis on Jakafi's 2028 US patent cliff, despite a diversifying revenue base and robust pipeline. Non-Jakafi segments grew over 50% YoY in 2025, with management guid
Knight Therapeutics Announces Approval of Additional Indication for MINJUVI® (tafasitamab) in Brazil
07:30am, Tuesday, 17'th Mar 2026
MONTREAL, March 17, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate, Uni
MONTREAL, March 17, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Argentine affiliate, Lab
Incyte Stock: Multiple Potential Catalysts In 2026 And Beyond
03:55pm, Monday, 16'th Mar 2026
Incyte remains attractively valued, trading at 12.5x 2026 EPS, well below sector medians, with 9% EPS and revenue growth expected. Jakafi, currently 60% of revenue, faces patent expiration in 2028; IN
Pre-Market Stock Futures: The futures are trading higher as we start the new trading week. There is an old saying, "Fool me once, shame on you; fool me twice, shame on me." Well, the buy-the-dip crowd
Glenmede Investment Management LP Has $53.58 Million Stock Position in Incyte Corporation $INCY
03:49am, Saturday, 14'th Mar 2026
Glenmede Investment Management LP lifted its position in Incyte Corporation (NASDAQ: INCY) by 1.2% during the undefined quarter, according to the company in its most recent disclosure with the Securit
Incyte (INCY) Down 4.2% Since Last Earnings Report: Can It Rebound?
12:30pm, Thursday, 12'th Mar 2026
Incyte (INCY) reported earnings 30 days ago. What's next for the stock?
Incyte Corporation (INCY) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
11:02am, Wednesday, 11'th Mar 2026
Incyte Corporation (INCY) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Incyte Corporation (INCY) Presents at Leerink Global Healthcare Conference 2026 Transcript
12:10pm, Tuesday, 10'th Mar 2026
Incyte Corporation (INCY) Presents at Leerink Global Healthcare Conference 2026 Transcript
US Bancorp DE Reduces Holdings in Incyte Corporation $INCY
04:16am, Tuesday, 10'th Mar 2026
US Bancorp DE lowered its stake in shares of Incyte Corporation (NASDAQ: INCY) by 63.2% during the undefined quarter, according to the company in its most recent Form 13F filing with the Securities an
INCY Wins EC Approval for Label Expansion of Oncology Drug Zynyz
01:15pm, Monday, 09'th Mar 2026
Incyte's Zynyz wins EU approval with chemotherapy for advanced anal cancer, marking the first systemic treatment for this indication.
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Announces the European Commission Approval of Zynyz (retifanlimab) for First-Line Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC).
Incyte Corporation $INCY Shares Bought by Fisher Asset Management LLC
03:56am, Friday, 06'th Mar 2026
Fisher Asset Management LLC lifted its stake in shares of Incyte Corporation (NASDAQ: INCY) by 33.5% in the third quarter, according to the company in its most recent disclosure with the SEC. The inst
Incyte Corporation (INCY) Presents at TD Cowen 46th Annual Health Care Conference Transcript
02:57pm, Monday, 02'nd Mar 2026
Incyte Corporation (INCY) Presents at TD Cowen 46th Annual Health Care Conference Transcript
The positive opinion is based on data from the Phase 3 BRAVE-AA-PEDS study, in which 42% of patients with severe alopecia areata (AA) reached 80% or more scalp hair coverage at 36 weeks The study is
